Haduvio™

A Dual-Action Approach to Chronic Cough

Haduvio has a novel approach to chronic cough by working on two important receptors that are critical mediators of cough, in both the central and peripheral nerves. Haduvio has a dual mechanism of action, acting as both an agonist (activator) to the kappa opioid receptor and as an antagonist (blocker) to the body’s mu opioid receptor. By targeting these receptors along the complete cough pathway, it has the potential to work regardless of whether the initial cough trigger originates in the lung or in the central nervous system.

Haduvio™

A Dual-Action Approach to Chronic Cough

Haduvio has a novel approach to chronic cough by working on two important receptors that are critical mediators of cough, in both the central and peripheral nerves. Haduvio has a dual mechanism of action, acting as both an agonist (activator) to the kappa opioid receptor and as an antagonist (blocker) to the body’s mu opioid receptor. By targeting these receptors along the complete cough pathway, it has the potential to work regardless of whether the initial cough trigger originates in the lung or in the central nervous system.

Central and Peripheral Pathways

The cause of chronic cough is thought to be the result of a hypersensitivity disorder where a stimulus, either chemical or mechanical, sends a message to the brain, through the brainstem, resulting in a cough. It is believed that IPF patients have an increased sensitivity to cough stimuli resulting in chronic cough. Since kappa and mu receptors are found in the respiratory regions of the brain, brainstem, lungs, and peripheral lung nerves, it is hypothesized that Haduvio can block the cough signal centrally and as well as peripherally and result in cough reduction independent of the initial stimuli.

Due to its dual mechanism of action (MOA), we believe Haduvio is well suited to address chronic cough across a variety of conditions.

For more information on our global clinical development programs, please visit our Pipeline page.